$18.15 Million in Sales Expected for Athenex Inc (NASDAQ:ATNX) This Quarter

Share on StockTwits

Analysts forecast that Athenex Inc (NASDAQ:ATNX) will announce $18.15 million in sales for the current quarter, Zacks reports. Two analysts have issued estimates for Athenex’s earnings, with estimates ranging from $15.10 million to $21.20 million. Athenex posted sales of $11.57 million in the same quarter last year, which suggests a positive year over year growth rate of 56.9%. The business is expected to announce its next earnings report on Tuesday, August 13th.

On average, analysts expect that Athenex will report full year sales of $79.83 million for the current financial year, with estimates ranging from $70.00 million to $90.60 million. For the next year, analysts forecast that the firm will report sales of $99.43 million, with estimates ranging from $73.50 million to $138.30 million. Zacks’ sales averages are a mean average based on a survey of research firms that cover Athenex.

Athenex (NASDAQ:ATNX) last posted its quarterly earnings data on Thursday, May 9th. The company reported ($0.53) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.45) by ($0.08). The business had revenue of $25.31 million during the quarter, compared to analyst estimates of $19.55 million. Athenex had a negative return on equity of 96.55% and a negative net margin of 189.86%.

Several equities research analysts have commented on ATNX shares. CIBC initiated coverage on Athenex in a research note on Thursday, May 2nd. They set an “outperform” rating and a $20.00 price objective for the company. Royal Bank of Canada reaffirmed an “outperform” rating and set a $31.00 price objective (up previously from $29.00) on shares of Athenex in a research report on Tuesday. BidaskClub raised Athenex from a “sell” rating to a “hold” rating in a report on Tuesday, May 14th. Oppenheimer began coverage on Athenex in a report on Thursday, May 2nd. They issued an “outperform” rating and a $20.00 target price on the stock. Finally, Zacks Investment Research lowered Athenex from a “hold” rating to a “sell” rating in a report on Tuesday, May 21st. Two analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $22.17.

Shares of ATNX stock traded up $0.40 on Friday, hitting $18.39. The company had a trading volume of 32,547 shares, compared to its average volume of 636,146. The stock has a market capitalization of $1.21 billion, a price-to-earnings ratio of -12.77 and a beta of -0.92. The company’s 50-day simple moving average is $15.41. The company has a current ratio of 2.22, a quick ratio of 1.85 and a debt-to-equity ratio of 0.57. Athenex has a twelve month low of $9.38 and a twelve month high of $20.90.

In other Athenex news, Director Jordan Kanfer acquired 2,500 shares of the stock in a transaction that occurred on Thursday, June 6th. The stock was acquired at an average price of $15.01 per share, with a total value of $37,525.00. Following the transaction, the director now directly owns 4,184 shares in the company, valued at $62,801.84. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Also, major shareholder Life Sciences Maste Perceptive acquired 130,000 shares of the stock in a transaction that occurred on Monday, June 17th. The shares were acquired at an average cost of $17.94 per share, with a total value of $2,332,200.00. The disclosure for this purchase can be found here. Insiders acquired a total of 308,210 shares of company stock worth $4,931,581 in the last quarter. 18.80% of the stock is currently owned by company insiders.

Several large investors have recently modified their holdings of ATNX. Rhumbline Advisers lifted its stake in Athenex by 51.8% during the fourth quarter. Rhumbline Advisers now owns 56,505 shares of the company’s stock valued at $717,000 after purchasing an additional 19,272 shares during the last quarter. Prudential Financial Inc. bought a new stake in shares of Athenex during the 4th quarter worth $147,000. BlackRock Inc. boosted its holdings in shares of Athenex by 0.9% during the 4th quarter. BlackRock Inc. now owns 3,616,333 shares of the company’s stock worth $45,892,000 after buying an additional 33,755 shares during the period. Private Advisor Group LLC boosted its holdings in Athenex by 6.2% in the 4th quarter. Private Advisor Group LLC now owns 17,091 shares of the company’s stock valued at $217,000 after purchasing an additional 991 shares during the period. Finally, Bank of New York Mellon Corp boosted its holdings in Athenex by 2.4% in the 4th quarter. Bank of New York Mellon Corp now owns 168,870 shares of the company’s stock valued at $2,143,000 after purchasing an additional 3,908 shares during the period. 31.21% of the stock is owned by institutional investors.

About Athenex

Athenex, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of various therapies for the treatment of cancer and related conditions in North America and Asia. It operates in three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform.

Featured Article: What impact do institutional investors have on markets?

Get a free copy of the Zacks research report on Athenex (ATNX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Athenex (NASDAQ:ATNX)

Receive News & Ratings for Athenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athenex and related companies with MarketBeat.com's FREE daily email newsletter.